Exhibit

Exhibit 99.4

ASML - Summary IFRS Consolidated Statement of Profit or Loss ^1,2



	Three months ended,				Twelve months ended,
	Dec 31,		Dec 31,		Dec 31,		Dec 31,
	2015		2016		2015		2016
(in millions EUR)

Net system sales	880.9		1,223.0		4,237.2		4,571.1
Net service and field option sales	553.3		684.4		2,050.2		2,223.7
Total net sales	1,434.2		1,907.4		6,287.4		6,794.8

Total cost of sales	(792.2	)	(1,078.1	)	(3,454.3	)	(3,897.0	)
Gross profit	642.0		829.3		2,833.1		2,897.8

Other income	20.8		23.5		83.2		93.8
Research and development costs	(189.8	)	(191.4	)	(710.2	)	(718.8	)
Selling, general and administrative costs	(89.5	)	(106.8	)	(345.3	)	(374.6	)
Operating income	383.5		554.6		1,860.8		1,898.2

Interest and other, net	1.6		77.1		(4.7	)	46.7
Income before income taxes	385.1		631.7		1,856.1		1,944.9

Income tax expense	(40.8	)	(101.5	)	(236.6	)	(388.0	)
Net income	344.3		530.2		1,619.5		1,556.9

ASML - Summary IFRS Consolidated Statement of Financial Position ^1,2



	Dec 31,	Dec 31,
	2015	2016
(in millions EUR)

ASSETS
Property, plant and equipment	1,620.7	1,687.2
Goodwill	2,647.8	4,898.3
Other intangible assets	2,018.5	2,882.3
Deferred tax assets	139.6	181.6
Finance receivables	124.0	117.2
Derivative financial instruments	81.8	89.5
Other assets	369.1	377.6
Total non-current assets	7,001.5	10,233.7

Inventories	2,573.7	2,780.9
Current tax assets	19.1	11.6
Derivative financial instruments	52.0	44.5
Finance receivables	280.5	447.4
Accounts receivable	803.7	700.2
Other assets	375.6	441.6
Short-term investments	950.0	1,150.0
Cash and cash equivalents	2,458.7	2,906.9
Total current assets	7,513.3	8,483.1

Total assets	14,514.8	18,716.8

EQUITY AND LIABILITIES
Equity	9,491.2	11,028.7

Long-term debt	1,125.5	3,071.8
Derivative financial instruments	1.9	38.1
Deferred and other tax liabilities	376.5	699.5
Provisions	2.4	20.5
Accrued and other liabilities	412.5	577.6
Total non-current liabilities	1,918.8	4,407.5

Provisions	2.4	1.8
Derivative financial instruments	19.0	75.8
Current portion of long-term debt	4.2	247.7
Current and other tax liabilities	3.7	201.9
Accrued and other liabilities	2,547.6	2,160.2
Accounts payable	527.9	593.2
Total current liabilities	3,104.8	3,280.6

Total equity and liabilities	14,514.8	18,716.8

ASML - Summary IFRS Consolidated Statement of Cash Flows ^1,2



	Three months ended,				Twelve months ended,
	Dec 31,		Dec 31,		Dec 31,		Dec 31,
	2015		2016		2015		2016
(in millions EUR)

CASH FLOWS FROM OPERATING ACTIVITIES
Net income	344.3		530.2		1,619.5		1,556.9

Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	98.4		174.4		359.9		503.6
Impairment	1.5		1.2		2.3		3.5
Loss on disposal of property, plant and equipment	—		1.4		1.6		5.2
Share-based payments	12.6		12.2		50.1		48.9
Allowance for doubtful receivables	1.2		0.8		3.9		3.2
Allowance for obsolete inventory	58.2		11.0		211.8		73.0
Deferred income taxes	20.5		0.3		134.8		172.4
Changes in assets and liabilities	537.8		560.4		15.6		(300.2	)
Net cash provided by (used in) operating activities	1,074.5		1,291.9		2,399.5		2,066.5

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(120.5	)	(95.9	)	(371.8	)	(316.3	)
Purchase of intangible assets	(89.0	)	(99.2	)	(371.4	)	(408.1	)
Purchase of available for sale securities	(950.0	)	(1,050.0	)	(950.0	)	(2,520.0	)
Maturity of available for sale securities	—		1,300.0		334.9		2,320.0
Cash from (used for) derivative financial instruments	(7.1	)	(9.4	)	(171.9	)	(15.0	)
Loans issued and other investments	—		(0.2	)	—		(7.4	)
Acquisition of subsidiaries (net of cash acquired)	—		(2,641.3	)	—		(2,641.3	)
Net cash provided by (used in) investing activities	(1,166.6	)	(2,596.0	)	(1,530.2	)	(3,588.1	)

CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid	—		—		(302.3	)	(445.9	)
Purchase of shares	(140.7	)	—		(564.9	)	(400.0	)
Net proceeds from issuance of shares	9.7		548.3		33.2		582.7
Net proceeds from issuance of notes	—		745.9		—		2,230.6
Repayment of debt	(1.1	)	(1.2	)	(3.6	)	(4.7	)
Net cash provided by (used in) financing activities	(132.1	)	1,293.0		(837.6	)	1,962.7

Net cash flows	(224.2	)	(11.1	)	31.7		441.1

Effect of changes in exchange rates on cash	2.0		5.0		7.5		7.1
Net increase (decrease) in cash and cash equivalents	(222.2	)	(6.1	)	39.2		448.2

ASML - Quarterly Summary IFRS Consolidated Statement of Profit or Loss ^1,2



	Three months ended,
		Dec 31,		Apr 3,		Jul 3,		Oct 2,		Dec 31,
		2015		2016		2016		2016		2016
(in millions EUR)

Net system sales		880.9		855.8		1,254.1		1,238.2		1,223.0
Net service and field option sales		553.3		477.4		485.5		576.4		684.4
Total net sales		1,434.2		1,333.2		1,739.6		1,814.6		1,907.4

Total cost of sales		(792.2	)	(784.4	)	(1,018.1	)	(1,016.4	)	(1,078.1	)
Gross profit		642.0		548.8		721.5		798.2		829.3

Other income		20.8		23.4		23.5		23.4		23.5
Research and development costs		(189.8	)	(199.1	)	(151.9	)	(176.4	)	(191.4	)
Selling, general and administrative costs		(89.5	)	(88.7	)	(90.3	)	(88.8	)	(106.8	)
Operating income		383.5		284.4		502.8		556.4		554.6

Interest and other, net		1.6		(0.3	)	—		(30.1	)	77.1
Income before income taxes		385.1		284.1		502.8		526.3		631.7

Income tax expense		(40.8	)	(53.3	)	(132.4	)	(100.8	)	(101.5	)
Net income		344.3		230.8		370.4		425.5		530.2

ASML - Quarterly Summary IFRS Consolidated Statement of Financial Position^1,2



	Dec 31,	Apr 3,	Jul 3,	Oct 2,	Dec 31,
	2015	2016	2016	2016	2016
(in millions EUR)

ASSETS
Property, plant and equipment	1,620.7	1,580.3	1,608.9	1,587.4	1,687.2
Goodwill	2,647.8	2,560.3	2,626.8	2,593.8	4,898.3
Other intangible assets	2,018.5	2,033.0	2,153.0	2,192.5	2,882.3
Deferred tax assets	139.6	123.4	165.2	168.6	181.6
Finance receivables	124.0	102.2	105.7	71.8	117.2
Derivative financial instruments	81.8	118.2	121.5	104.8	89.5
Other assets	369.1	365.6	367.5	369.7	377.6
Total non-current assets	7,001.5	6,883.0	7,148.6	7,088.6	10,233.7

Inventories	2,573.7	2,750.0	2,715.3	2,696.9	2,780.9
Current tax assets	19.1	96.0	178.0	143.5	11.6
Derivative financial instruments	52.0	56.8	43.0	48.4	44.5
Finance receivables	280.5	446.5	524.0	663.5	447.4
Accounts receivable	803.7	753.2	732.4	858.4	700.2
Other assets	375.6	386.3	395.0	417.5	441.6
Short-term investments	950.0	1,075.0	1,000.0	1,400.0	1,150.0
Cash and cash equivalents	2,458.7	2,063.4	1,926.1	2,913.0	2,906.9
Total current assets	7,513.3	7,627.2	7,513.8	9,141.2	8,483.1

Total assets	14,514.8	14,510.2	14,662.4	16,229.8	18,716.8

EQUITY AND LIABILITIES
Equity	9,491.2	9,429.4	9,299.5	9,690.6	11,028.7

Long-term debt	1,125.5	1,144.3	901.9	2,390.6	3,071.8
Derivative financial instruments	1.9	1.4	1.2	0.8	38.1
Deferred and other tax liabilities	376.5	378.6	405.0	472.4	699.5
Provisions	2.4	—	12.6	16.5	20.5
Accrued and other liabilities	412.5	309.7	322.1	386.7	577.6
Total non-current liabilities	1,918.8	1,834.0	1,642.8	3,267.0	4,407.5

Provisions	2.4	4.0	2.9	2.4	1.8
Derivative financial instruments	19.0	24.8	34.3	29.8	75.8
Current portion of long-term debt	4.2	4.2	253.6	250.4	247.7
Current and other tax liabilities	3.7	8.6	170.9	131.1	201.9
Accrued and other liabilities	2,547.6	2,560.7	2,524.2	2,227.2	2,160.2
Accounts payable	527.9	644.5	734.2	631.3	593.2
Total current liabilities	3,104.8	3,246.8	3,720.1	3,272.2	3,280.6

Total equity and liabilities	14,514.8	14,510.2	14,662.4	16,229.8	18,716.8

ASML - Quarterly Summary IFRS Consolidated Statement of Cash Flows ^1,2



	Three months ended,
		Dec 31,		Apr 3,		Jul 3,		Oct 2,		Dec 31,
		2015		2016		2016		2016		2016
(in millions EUR)

CASH FLOWS FROM OPERATING ACTIVITIES
Net income		344.3		230.8		370.4		425.5		530.2

Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization		98.4		101.3		103.9		124.0		174.4
Impairment		1.5		0.5		0.4		1.4		1.2
Loss on disposal of property, plant and equipment		—		1.2		0.9		1.7		1.4
Share-based payments		12.6		13.6		10.5		12.6		12.2
Allowance for doubtful receivables		1.2		0.9		0.8		0.7		0.8
Allowance for obsolete inventory		58.2		36.6		22.5		2.9		11.0
Deferred income taxes		20.5		23.1		81.9		67.1		0.3
Changes in assets and liabilities		537.8		(335.2	)	11.9		(537.3	)	560.4
Net cash provided by (used in) operating activities		1,074.5		72.8		603.2		98.6		1,291.9

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(120.5	)	(55.2	)	(98.9	)	(66.3	)	(95.9	)
Purchase of intangible assets		(89.0	)	(82.2	)	(123.3	)	(103.4	)	(99.2	)
Purchase of available for sale securities		(950.0	)	(350.0	)	(350.0	)	(770.0	)	(1,050.0	)
Maturity of available for sale securities		—		225.0		425.0		370.0		1,300.0
Cash from (used for) derivative financial instruments		(7.1	)	1.1		7.7		(14.4	)	(9.4	)
Loans issued and other investments		—		—		(6.0	)	(1.2	)	(0.2	)
Acquisition of subsidiaries		—		—		—		—		(2,641.3	)
Net cash provided by (used in) investing activities		(1,166.6	)	(261.3	)	(145.5	)	(585.3	)	(2,596.0	)

CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid		—		—		(445.9	)	—		—
Purchase of shares		(140.7	)	(213.5	)	(171.9	)	(14.6	)	—
Net proceeds from issuance of shares		9.7		10.6		12.1		11.7		548.3
Net proceeds from issuance of notes		—		—		—		1,484.7		745.9
Repayment of debt		(1.1	)	(1.2	)	(1.2	)	(1.1	)	(1.2	)
Net cash provided by (used in) financing activities		(132.1	)	(204.1	)	(606.9	)	1,480.7		1,293.0

Net cash flows		(224.2	)	(392.6	)	(149.2	)	994.0		(11.1	)

Effect of changes in exchange rates on cash		2.0		(2.7	)	11.9		(7.1	)	5.0
Net increase (decrease) in cash and cash equivalents		(222.2	)	(395.3	)	(137.3	)	986.9		(6.1	)

Notes to the Summary IFRS Consolidated Financial Statements

Basis of Preparation

The accompanying Summary Consolidated Financial Statements are stated in millions of euros unless indicated otherwise. The accompanying Summary Consolidated Financial Statements have been prepared in conformity with International Financial Reporting Standards as adopted by the EU (“IFRS”) accounting principles generally accepted in the Netherlands for companies quoted on Euronext Amsterdam. For further details on our Summary of Significant Accounting Policies refer to the Notes to the Consolidated Financial Statements as recorded in our Statutory Annual Report which is available on www.asml.com. Further disclosures, as required under IFRS in annual reports and interim reporting (IAS 34), are not included in the Summary Consolidated Financial Statements.

For internal and external reporting purposes, we apply accounting principles generally accepted in the United States of America ("US GAAP"). US GAAP is our primary accounting standard for the setting of financial and operational performance targets.

ASML – Reconciliation US GAAP – IFRS ^1,2



Net income	Three months ended,				Twelve months ended,
	Dec 31,		Dec 31,		Dec 31,		Dec 31,
	2015		2016		2015		2016
(in millions EUR)
Net income based on US GAAP	292.4		524.2		1,387.2		1,471.9
Development expenditures (see Note 1)	55.0		16.8		244.7		190.6
Income taxes (see Note 2)	(2.8	)	(10.8	)	(14.5	)	(106.4	)
Other	(0.3	)	—		2.1		0.8
Net income based on IFRS	344.3		530.2		1,619.5		1,556.9

Notes to the reconciliation from US GAAP to IFRS

Note 1 Development expenditures

Under US GAAP, ASML applies ASC 730, "Research and Development". In accordance with ASC 730, ASML charges costs relating to research and development to operating expense as incurred.

Under IFRS, ASML applies IAS 38, "Intangible Assets". In accordance with IAS 38, ASML capitalizes certain development expenditures that are amortized over the expected useful life of the related product generally ranging between one and five years. Amortization starts when the developed product is ready for volume production.

Note 2 Income taxes

Under US GAAP, the elimination of unrealized net income from intercompany transactions that are eliminated from the carrying amount of assets in consolidation give rise to a temporary difference for which prepaid taxes must be recognized in consolidation. Contrary to IFRS, the prepaid taxes under US GAAP are calculated based on the tax rate applicable in the seller’s rather than the purchaser’s tax jurisdiction.

Under IFRS, ASML applies IAS 12, "Income Taxes". In accordance with IAS 12 unrealized net income resulting from intercompany transactions that are eliminated from the carrying amount of assets in consolidation give rise to a temporary difference for which deferred taxes must be recognized in consolidation. The deferred taxes are calculated based on the tax rate applicable in the purchaser’s tax jurisdiction.

This document contains statements relating to certain projections and business trends that are forward-looking, including statements with respect to expected trends and outlook, including expected customer insertion of EUV in volume manufacturing, including expected volume orders, systems backlog, expected financial results and trends for the first quarter of 2017, including expected sales, other income, gross margin, R&D and SG&A expenses and effective annualized tax rate, annual revenue opportunity for ASML and EPS potential by 2020, including further growth potential into the next decade, expected industry trends and expected trends in the business environment, statements with respect to the proposed minority stake in Carl Zeiss SMT, including statements that such investment will secure the extension of EUV beyond the next decade and funding for next generation EUV technology, statements with respect to EUV targets, manufacturing, supply chain and service capabilities, and ASML’s commitment to secure system performance, shipments and support for volume manufacturing, including availability, productivity, throughput and shipments, including timing of shipments and the ability to support a larger installed base, shrink being a key driver supporting innovation and providing long-term industry growth, lithography enabling affordable shrink and delivering value to customers, expected industry adoption of EUV and statements with respect to the intent of customers to insert EUV into production, the extension of EUV beyond the next decade, the expected continuation of Moore's law and that EUV will continue to enable Moore’s law and drive long term value, intention to return excess cash to shareholders, and statements about our proposed dividend, dividend policy and intention to repurchase shares and statements with respect to the share repurchase plan. You can generally identify these statements by the use of words like "may", "will

", "could", "should", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast", "potential", "intend", "continue", "targets", "commits to secure" and variations of these words or comparable words. These statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and our future financial results and readers should not place undue reliance on them. Forward-looking statements do not guarantee future performance and involve risks and uncertainties. These risks and uncertainties include, without limitation, economic conditions, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), including the impact of general economic conditions on consumer confidence and demand for our customers' products, competitive products and pricing, the impact of any manufacturing efficiencies and capacity constraints, performance of our systems, the continuing success of technology advances and the related pace of new product development and customer acceptance of new products including EUV, the number and timing of EUV systems expected to be shipped and recognized in revenue, delays in EUV systems production and development and volume production by customers, including meeting development requirements for volume production, our ability to enforce patents and protect intellectual property rights, the risk of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates, changes in tax rates, available cash and liquidity, our ability to refinance our indebtedness, distributable reserves for dividend payments and share repurchases and timing of resumption of the share repurchase plan, and other risks indicated in the risk factors included in ASML's Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. These forward-looking statements are made only as of the date of this document. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.


¹	These financial statements are unaudited.


²	Numbers have been rounded.